Apomorphine to Uprima: the development of a practical erectogenic drug: a personal perspective.
The development process for apomorphine SL as an effective treatment for patients with erectile dysfunction has been somewhat unusual. As often is the case, much of the impetus for the basic research originated in academia. However, somewhat unusually, the impetus for early stage clinical research also lay in the hands of the academics. This article represents a historical perspective from one of those involved throughout.
Morales
A
A
Department of Urology Queen's University, Kingston, Canada. moralesa@post.queensu.ca
D000284:Administration, Oral; D000818:Animals; D001058:Apomorphine / Q000008:administration & dosage / Q000266:history* / Q000627:therapeutic use; D002170:Canada; D017327:Clinical Trials, Phase IV as Topic; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000266:history* / Q000627:therapeutic use; D017277:Drug Approval; D007172:Erectile Dysfunction / Q000188:drug therapy / Q000266:history*; D049672:History, 19th Century; D049673:History, 20th Century; D006801:Humans; D008297:Male; D010410:Penile Erection / Q000187:drug effects*; D013678:Technology, Pharmaceutical / Q000266:history*
D018491:Dopamine Agonists; D001058:Apomorphine